

Chronic Steatohepatitis (NASH)-United States Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/OBFBCBCADCDCDEN.html>

Date: December 2017

Pages: 137

Price: US\$ 3,480.00 (Single User License)

ID: OBFBCBCADCDCDEN

Abstracts

Report Summary

Chronic Steatohepatitis (NASH)-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Chronic Steatohepatitis (NASH) industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole United States and Regional Market Size of Chronic Steatohepatitis (NASH) 2013-2017, and development forecast 2018-2023

Main market players of Chronic Steatohepatitis (NASH) in United States, with company and product introduction, position in the Chronic Steatohepatitis (NASH) market
Market status and development trend of Chronic Steatohepatitis (NASH) by types and applications

Cost and profit status of Chronic Steatohepatitis (NASH), and marketing status

Market growth drivers and challenges

The report segments the United States Chronic Steatohepatitis (NASH) market as:

United States Chronic Steatohepatitis (NASH) Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

New England

The Middle Atlantic

The Midwest

The West

The South

Southwest

United States alcoholic Steatohepatitis (NASH) Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Weight Loss Treatment

Insulin-Sensitizing Agents

Lipid-Lowering Drugs

Antioxidants

Other Agents

United States alcoholic Steatohepatitis (NASH) Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and
Market Analysis)

Hospital

Clinics

Drug Store

Research institute

Others

United States alcoholic Steatohepatitis (NASH) Market: Players Segment Analysis
(Company and Product introduction, alcoholic Steatohepatitis (NASH) Sales Volume,
Revenue, Price and Gross Margin):

Boehringer Ingelheim

Cerenis Therapeutics

Connexios Life Sciences

Genfit

Islet Sciences

Nimbus Therapeutics

Verva Pharmaceuticals

Viking Therapeutics

Astazeneca Plc

Galmed Pharmaceuticals Ltd.

GENFIT SA

Gilead Science

Novo Nordisk
Immuron Ltd
Intercepts Pharmaceuticals
Enzo Biochem, Inc
Tobira Therapeutics, Inc.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF OHOLIC STEATOHEPATITIS (NASH)

- 1.1 Definition of oholic Steatohepatitis (NASH) in This Report
- 1.2 Commercial Types of oholic Steatohepatitis (NASH)
 - 1.2.1 Weight Loss Treatment
 - 1.2.2 Insulin-Sensitizing Agents
 - 1.2.3 Lipid-Lowering Drugs
 - 1.2.4 Antioxidants
 - 1.2.5 Other Agents
- 1.3 Downstream Application of oholic Steatohepatitis (NASH)
 - 1.3.1 Hospital
 - 1.3.2 Clinics
 - 1.3.3 Drug Store
 - 1.3.4 Research institute
 - 1.3.5 Others
- 1.4 Development History of oholic Steatohepatitis (NASH)
- 1.5 Market Status and Trend of oholic Steatohepatitis (NASH) 2013-2023
 - 1.5.1 United States oholic Steatohepatitis (NASH) Market Status and Trend 2013-2023
 - 1.5.2 Regional oholic Steatohepatitis (NASH) Market Status and Trend 2013-2023

CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of oholic Steatohepatitis (NASH) in United States 2013-2017
- 2.2 Consumption Market of oholic Steatohepatitis (NASH) in United States by Regions
 - 2.2.1 Consumption Volume of oholic Steatohepatitis (NASH) in United States by Regions
 - 2.2.2 Revenue of oholic Steatohepatitis (NASH) in United States by Regions
- 2.3 Market Analysis of oholic Steatohepatitis (NASH) in United States by Regions
 - 2.3.1 Market Analysis of oholic Steatohepatitis (NASH) in New England 2013-2017
 - 2.3.2 Market Analysis of oholic Steatohepatitis (NASH) in The Middle Atlantic 2013-2017
 - 2.3.3 Market Analysis of oholic Steatohepatitis (NASH) in The Midwest 2013-2017
 - 2.3.4 Market Analysis of oholic Steatohepatitis (NASH) in The West 2013-2017
 - 2.3.5 Market Analysis of oholic Steatohepatitis (NASH) in The South 2013-2017
 - 2.3.6 Market Analysis of oholic Steatohepatitis (NASH) in Southwest 2013-2017
- 2.4 Market Development Forecast of oholic Steatohepatitis (NASH) in United States 2018-2023

2.4.1 Market Development Forecast of oholic Steatohepatitis (NASH) in United States 2018-2023

2.4.2 Market Development Forecast of oholic Steatohepatitis (NASH) by Regions 2018-2023

CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES

3.1 Whole United States Market Status by Types

3.1.1 Consumption Volume of oholic Steatohepatitis (NASH) in United States by Types

3.1.2 Revenue of oholic Steatohepatitis (NASH) in United States by Types

3.2 United States Market Status by Types in Major Countries

3.2.1 Market Status by Types in New England

3.2.2 Market Status by Types in The Middle Atlantic

3.2.3 Market Status by Types in The Midwest

3.2.4 Market Status by Types in The West

3.2.5 Market Status by Types in The South

3.2.6 Market Status by Types in Southwest

3.3 Market Forecast of oholic Steatohepatitis (NASH) in United States by Types

CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of oholic Steatohepatitis (NASH) in United States by Downstream Industry

4.2 Demand Volume of oholic Steatohepatitis (NASH) by Downstream Industry in Major Countries

4.2.1 Demand Volume of oholic Steatohepatitis (NASH) by Downstream Industry in New England

4.2.2 Demand Volume of oholic Steatohepatitis (NASH) by Downstream Industry in The Middle Atlantic

4.2.3 Demand Volume of oholic Steatohepatitis (NASH) by Downstream Industry in The Midwest

4.2.4 Demand Volume of oholic Steatohepatitis (NASH) by Downstream Industry in The West

4.2.5 Demand Volume of oholic Steatohepatitis (NASH) by Downstream Industry in The South

4.2.6 Demand Volume of oholic Steatohepatitis (NASH) by Downstream Industry in Southwest

4.3 Market Forecast of oholic Steatohepatitis (NASH) in United States by Downstream

Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)

5.1 United States Economy Situation and Trend Overview

5.2 oholic Steatohepatitis (NASH) Downstream Industry Situation and Trend Overview

CHAPTER 6 OHOLIC STEATOHEPATITIS (NASH) MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES

6.1 Sales Volume of oholic Steatohepatitis (NASH) in United States by Major Players

6.2 Revenue of oholic Steatohepatitis (NASH) in United States by Major Players

6.3 Basic Information of oholic Steatohepatitis (NASH) by Major Players

6.3.1 Headquarters Location and Established Time of oholic Steatohepatitis (NASH) Major Players

6.3.2 Employees and Revenue Level of oholic Steatohepatitis (NASH) Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 OHOLIC STEATOHEPATITIS (NASH) MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Boehringer Ingelheim

7.1.1 Company profile

7.1.2 Representative oholic Steatohepatitis (NASH) Product

7.1.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim

7.2 Cerenis Therapeutics

7.2.1 Company profile

7.2.2 Representative oholic Steatohepatitis (NASH) Product

7.2.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Cerenis Therapeutics

7.3 Connexios Life Sciences

7.3.1 Company profile

7.3.2 Representative oholic Steatohepatitis (NASH) Product

7.3.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of

Connexios Life Sciences

7.4 Genfit

7.4.1 Company profile

7.4.2 Representative oholic Steatohepatitis (NASH) Product

7.4.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Genfit

7.5 Islet Sciences

7.5.1 Company profile

7.5.2 Representative oholic Steatohepatitis (NASH) Product

7.5.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Islet

Sciences

7.6 Nimbus Therapeutics

7.6.1 Company profile

7.6.2 Representative oholic Steatohepatitis (NASH) Product

7.6.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of

Nimbus Therapeutics

7.7 Verva Pharmaceuticals

7.7.1 Company profile

7.7.2 Representative oholic Steatohepatitis (NASH) Product

7.7.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Verva

Pharmaceuticals

7.8 Viking Therapeutics

7.8.1 Company profile

7.8.2 Representative oholic Steatohepatitis (NASH) Product

7.8.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Viking

Therapeutics

7.9 Astazeneca Plc

7.9.1 Company profile

7.9.2 Representative oholic Steatohepatitis (NASH) Product

7.9.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of

Astazeneca Plc

7.10 Galmed Pharmaceuticals Ltd.

7.10.1 Company profile

7.10.2 Representative oholic Steatohepatitis (NASH) Product

7.10.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of

Galmed Pharmaceuticals Ltd.

7.11 GENFIT SA

7.11.1 Company profile

7.11.2 Representative oholic Steatohepatitis (NASH) Product

7.11.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of

GENFIT SA

7.12 Gilead Science

7.12.1 Company profile

7.12.2 Representative oholic Steatohepatitis (NASH) Product

7.12.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Gilead Science

7.13 Novo Nordisk

7.13.1 Company profile

7.13.2 Representative oholic Steatohepatitis (NASH) Product

7.13.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Novo Nordisk

7.14 Immuron Ltd

7.14.1 Company profile

7.14.2 Representative oholic Steatohepatitis (NASH) Product

7.14.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Immuron Ltd

7.15 Intercepts Pharmaceuticals

7.15.1 Company profile

7.15.2 Representative oholic Steatohepatitis (NASH) Product

7.15.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Intercepts Pharmaceuticals

7.16 Enzo Biochem, Inc

7.17 Tobira Therapeutics, Inc.

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)

8.1 Industry Chain of oholic Steatohepatitis (NASH)

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)

9.1 Cost Structure Analysis of oholic Steatohepatitis (NASH)

9.2 Raw Materials Cost Analysis of oholic Steatohepatitis (NASH)

9.3 Labor Cost Analysis of oholic Steatohepatitis (NASH)

9.4 Manufacturing Expenses Analysis of oholic Steatohepatitis (NASH)

CHAPTER 10 MARKETING STATUS ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: oholic Steatohepatitis (NASH)-United States Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/OBFBCBCADCEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OBFBCBCADCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970